Hims & Hers stock falls after Eli Lilly's weight-loss drug dropped from shortage list
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed them from its shortage list — signaling the pharmaceutical giant's ability to now meet market demand.
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...
Health care stocks underperformed the broader market in 2023, with many companies falling short of their profit targets, and ...
Eli Lilly announced Wednesday it will invest another $4.5 billion into a new facility at the states controversial LEAP ...
In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Eli Lilly & Co (LLY – Research ...
Eli Lilly has announced a $4.5bn investment to establish the Lilly Medicine Foundry for drug production and manufacturing ...
U.S. drugmaker Eli Lilly said on Wednesday it will invest $4.5 billion to create a new center for advanced manufacturing and ...
Drugmaker Eli Lilly said it will spend $4.5 billion to build a new manufacturing research hub in Indiana, where it will develop new methods of producing complicated types of medicines. The new investm ...
Eli Lilly and Company will invest an additional $4.5 billion in Boone County to create a new center for advanced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback